Paricalcitol

Research use only, not for human use.

An analog of 1,25-dihydroxyergocalciferol that acts as a selective vitamin D receptor (VDR) activator.

An analog of 1,25-dihydroxyergocalciferol that acts as a selective vitamin D receptor (VDR) activator; significantly decreases parathyroid hormone levels with no changes in calcium and phosphorous, also reduces serum concentrations of IL-6 and TNF-α compared to baseline; orally active.Hyperparathyroidism Approved(In Vitro):Paricalcitol (3×10-8 M; HP + PC) produces a significant reduction in calcification relative to the observed in cells in HP medium. Paricalcitol causes a reduction in the levels of nuclear β-catenin to a level similar to that observed in control cells.(In Vivo):Paricalcitol (300 ng/kg/day) significantly decreases Tau, and prevents LV dysfunction in mice. Paricalcitol reduces mRNA expression of ANP, fibronectin and collagen III in the TAC-pari mice.

——

——

Zemplar

Metabolic Enzyme/Protease

Vitamin

Vitamin

Endocrinology

Hyperparathyroidism

131918-61-1

416.6365

C27H44O3

>98% (HPLC)

10 mM in DMSO

O[C@@H](C[C@H](O)C/1)CC1=C\C=C2CCC[C@@]3(C)[C@@]/2([H])CC[C@]3([H])[C@H](C)/C=C/[C@H](C)C(C)(O)C

1,3-Cyclohexanediol, 5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3R,5Z)-

(-20℃)

With Ice Pack

≥ 2 years